Annovis Bio announced last patient last visit for its phase II/III trial of #buntanetap in Alzheimer’s Disease. In total, 327 patients completed the study. Learn more at https://lnkd.in/g-nX-7aK
Annovis Bio, Inc.
Biotechnology Research
Malvern, Pennsylvania 2,354 followers
It’s time for a new direction in treating Alzheimer’s, Parkinson’s and related neurodegenerative diseases.
About us
Annovis Bio, Inc.’s novel approach to addressing chronic and acute neurodegeneration offers new hope in the fight against the largest unmet need of an aging population. Annovis is a clinical stage, drug platform company focused primarily on drugs for chronic neurodegeneration—AD, its orphan indication AD-DS and PD. Additionally, we have a compound to treat acute neurodegeneration—traumatic brain injury (TBI) and stroke—and a third compound for advanced AD. Our lead compound is ANVS-401, a small, once a day, orally administered, brain penetrant inhibitor of neurotoxic proteins. We believe that ANVS-401 has the potential to be the first drug to interfere with the underlying mechanism of neurodegeneration. The biological activity of ANVS-401 has been evaluated in 19 animal studies conducted in leading institutions such as the Karolinska Institute, Columbia University and Harvard University. We have also conducted three clinical trials with 125 humans including two safety studies in 120 healthy volunteers and a proof-of-concept study in five MCI patients. These studies showed that ANVS-401 was well tolerated and we saw promising clinical signals: ANVS-401 reduced and normalized the levels of APP, tau and aSYN (aSYN is an unpublished observation), - neurotoxic proteins that are the main cause of neurodegeneration -- back to the levels seen in healthy volunteers and statistically lowered inflammation. We are presently conducting a Phase 2a study in AD patients in collaboration with the Alzheimer Disease Cooperative Study (ADCS) group and plan to initiate a second Phase 2a proof-of-concept study of ANVS-401 in the first quarter of 2020 with 50 PD patients. We believe AD and PD are two of the largest medical needs of the aging U.S. population, and two potentially large markets, once a DMD has been developed and approved. Therefore, we desire to demonstrate ANVS-401's efficacy in both indications.
- Website
-
http://annovisbio.com/
External link for Annovis Bio, Inc.
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Malvern, Pennsylvania
- Type
- Privately Held
- Founded
- 2008
- Specialties
- Neurodegeneration, Alzheimer’s, Parkinson’s, Alzheimer’s in Down Syndrome, Axonal Transport, Traumatic Brain Injury, APP, tau, aSYN, neurotoxic proteins, APP/Ab (APP), tau/phospho-tau, and a-Synuclein (a-SYN)
Locations
-
Primary
101 Lindenwood Dr.
Suite #225
Malvern, Pennsylvania 19355, US
Employees at Annovis Bio, Inc.
Updates
-
Annovis today announced corporate updates and financial results for 1Q 2024. For more information, see the release at https://lnkd.in/es7bWcEw
-
Annovis Bio announced unblinding for the Phase III data from Parkinson's study and shares the topline data is now expected in June. Read more for details -> https://lnkd.in/ecbQ5zyD
-
Breaking news! Annovis Bio announced significant data from its Phase II/III study of #buntanetap in patients with early #AlzheimersDisease. Buntanetap, a translational inhibitor of neurotoxic proteins, showed dose-dependent improvement of cognition in early AD patients. More information and full release here -> https://lnkd.in/eUBnwDNr
-
How does #buntanetap work? It targets the iron regulatory protein 1 (IRP1) and keeps the mRNA bound inhibiting the translation of neurotoxic proteins. Amyloid precursor protein (APP) is one of such neurotoxic proteins, which is crucial for the production of amyloid beta, a key player in #Alzheimers. Check our latest publication that provides further support for buntanetap's role as an inhibitor of APP in humans. Check our latest publication https://lnkd.in/eQGWSmJu
-
Save the date and reserve your tickets! Next week Maria L. Maccecchini, PhD will join an inspiring discussion at the Spring 2024 Journal Launch Event. Find more information in the post below.
Save the date! Penn Healthcare Review is proud to announce their Spring 2024 Journal Launch Event on April 17th, 2024. Featured speakers include Dr. Virginia Lee, 2020 Breakthrough Life Sciences Prize Winner; Dr. Haichen Yang, VP of Clinical Research at Amicus Therapeutics; and Dr. Maria L. Maccecchini, CEO of Annovis Bio, Inc.. Make sure to secure your ticket ASAP: https://lnkd.in/gGKNtYsZ Watch the launch video here: https://lnkd.in/gA-rtV6P
-
This #WorldParkinsonsDay, Annovis joins Parkinson's Spark to encourage #Parkinsons community to share your Spark! Spark is a new global symbol for #PD awareness. Visit https://lnkd.in/d99TPRst to learn how advocates unite globally to raise awareness.
-
April is #ParkinsonsAwarenessMonth! Raising awareness about #Parkinsons not only promotes unity and support within communities but also facilitates education, empowering individuals to navigate their journey with greater knowledge. #PD Explore the #ABCsofPD https://lnkd.in/gEnv-gX
-
Annovis Bio announces corporate updates and financial results for 4Q and full year 2023. Full release at -> https://lnkd.in/edYuZ86m
-
Buntanetap is a translational inhibitor of APP! Further look at earlier Phase 1b study by ADCS unveils confirmatory data in a new publication. Check out the summary here https://lnkd.in/e7YANkNZ